Evolve Your Success
JULY 25, 2023
Working in the field of spine medical sales is not just a job, but an extraordinary expedition driven by purpose, resilience, and ingenuity. In today’s episode, we dive into the world of spine medical sales with Taylor Laneville. He is a dynamic individual who transitioned from being an organic chemist to a highly esteemed medical sales consultant.
Fierce Pharma
JULY 26, 2023
As with Novo Nordisk’s popular offering for obesity, Wegovy, demand for Eli Lilly’s dual GIP/GLP-1 agonist Mounjaro appears to be outpacing supply once again. | The U.S. Food and Drug Administration has added a fourth dose of Lilly’s popular new diabetes med to its drug shortage database. The agency also expects supply issues with three other doses to persist longer than previously thought.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PM360
JULY 26, 2023
As biosimilars make inroads across various disease states, oncology especially appears to have embraced the new breed of therapies. Biosimilar adoption, however, is not as simple as picking the lowest-cost option, according to one expert. Deciding which biosimilars to use requires a complex set of considerations for oncology clinics, notes Andre Harvin, PharmD, Executive Director of Pharmacy and Oncology Services at Cone Health.
Pharma Marketing Network
JULY 25, 2023
In today’s digital world, partnering with a competent and reliable digital marketing agency is crucial for businesses seeking to enhance their online presence, reach their target audience, and achieve their marketing goals. However, with countless agencies available, it can be overwhelming to find the right one that aligns with your business objectives.
Spotio
JULY 25, 2023
B2B sales has evolved over the years. Cold calling and direct mail are still useful for some sales processes, but the way in which we do business has changed a lot. More companies are investing in B2B sales teams — inside and outside — across a range of industries. The B2B buying process now has more decision-makers and touchpoints than it did just a few years ago.
Fierce Pharma
JULY 28, 2023
On Monday during a quarterly earnings call, when Biogen CEO Chris Viehbacher was asked about the company’s potential to execute M&A, he randomly offered “we’ve got, I think, about $7.3 billion | Biogen has revealed a proposal to acquire Reata Pharmaceuticals for $7.3 billion. The Texas-based rare disease specialist brings newly approved Skyclarys, the first treatment for the neurologic disorder Friedreich’s ataxia with peak sales potential of $1.5 billion.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
Pharma Marketing Network
JULY 27, 2023
Developing strong and meaningful relationships with Healthcare Professionals (HCPs) is vital for healthcare organizations, pharmaceutical companies, and medical device manufacturers alike. These partnerships not only improve patient outcomes but also foster mutual trust and collaboration. In this blog, we will explore five effective strategies to enhance your relationship-building efforts with HCPs and ultimately achieve better healthcare outcomes.
MedCity News
JULY 26, 2023
More than 600 rural U.S. hospitals — which is more than 30% of the country’s rural hospitals — are at risk of closing due to their financial instability, according to a new report. The report argued that the dire financial situation among the nation’s rural hospitals stems from two main issues: low financial reserves and inadequate payments from private health plans.
Fierce Pharma
JULY 27, 2023
Eli Lilly continues to bolster the case for its dual GIP/GLP-1 agonist tirzepatide as a powerful weight loss agent. | Also known as Mounjaro in its approved type 2 diabetes indication, tirzepatide helped patients across two trials—Surmount-3 and Surmount-4—lose up to 26.6% of their body weight, Lilly said Thursday.
PM360
JULY 26, 2023
Digital fireworks were launched just hours after the July 4 th holiday in the U.S. with the official launch of Threads by Meta, a new platform that is a direct competitor of Twitter. It should be of no surprise to anyone that a flurry of Twitter competitors is now entering the marketplace. Ever since Elon Musk’s purchase of Twitter, a target has been on the back of one of the original and most polarizing social platforms.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Pharma Marketing Network
JULY 25, 2023
Ads Manager is a powerful platform that can help pharma companies reach their target audience and achieve their marketing goals. One of the ways to do this is to customize your audience. This means targeting your ads to people who are most likely to be interested in your products or services. Here are some tips for customizing your audience in Ads Manager for the pharma industry: Use demographics: You can target your ads based on demographics, such as age, gender, location, and interests.
MedCity News
JULY 25, 2023
Pear Therapeutics was once regarded as a digital therapeutics pioneer, but its spiral into bankruptcy has the industry searching for the best path forward. While some favor going direct to consumers, others say the solution is in generating more robust clinical trial data to persuade hesitant payers.
Fierce Pharma
JULY 27, 2023
To Roche’s pharma chief Teresa Graham, no word better describes the company’s eye drug Vabysmo right now than “momentum.” | To Roche’s pharma chief Teresa Graham, no word better describes the company’s eye drug Vabysmo right now than “momentum.” Approved by the FDA in January 2022, Vabysmo already crossed the one-billion-dollar sales mark in the first half of 2023.
PM360
JULY 26, 2023
Since passage of the Inflation Reduction Act (IRA) in August 2022, the focus of many industry analysts and pharmaceutical companies has been on two important first order concerns: identifying products to be negotiated by the Centers for Medicare & Medicaid Services (CMS) and assessing the direct impact on prices. Most companies have now completed the critical analyses associated with these direct effects.
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
Pharma Marketing Network
JULY 26, 2023
The Food and Drug Administration (FDA) plays a critical role in regulating the pharmaceutical industry and ensuring that medications and medical devices marketed to the public are safe, effective, and appropriately labeled. One of the FDA’s enforcement mechanisms is the issuance of marketing violation letters to pharmaceutical companies found in violation of advertising and promotion regulations.
European Pharmaceutical Review
JULY 25, 2023
Axatilimab, an anti-CSF-1R antibody to treat chronic graft-versus-host disease (GVHD) has, in a pivotal Phase II trial, demonstrated overall response rates (ORR) of 74 percent, 67 percent and 50 percent, within the first six months of treatment. “[It] is the first investigational chronic GVHD treatment to target inflammation and fibrosis through the inhibition of disease associated macrophages,” stated Michael A Metzger, Chief Executive Officer of Syndax Pharmaceuticals.
Fierce Pharma
JULY 25, 2023
In reporting its first-quarter earnings, Biogen said it would halt the development of at least four investigational drugs to allow the company to focus on more lucrative opportunities. | In a sizable cost-cutting measure, Biogen will lay off 1,000 employees by 2025, it announced in presenting its second quarter earnings. With the company starting 2023 with 8,725 employees, that’s an 11.5% reduction of the workforce.
PM360
JULY 26, 2023
Would it surprise you to know that the COVID-19 pandemic turned pharmacy priorities on its head, which could have the potential of morphing pharmacies into full-fledge healthcare centers over the long term? Pharmacy technicians (aka “techs”) and pharmacists alike were affected by COVID-19. Adding responsibilities of testing for COVID-19 and administering the vaccine in mass volumes when it became available, pharmacists and techs had to shuffle workload and priorities in a way that supported this
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
MedCity News
JULY 27, 2023
I invite insurance companies to engage in meaningful dialogue with urgent care providers to understand the challenges they face and explore fair reimbursement models that reflect the value they bring to patients.
Pharma Marketing Network
JULY 25, 2023
Google Ads is a great way to reach a wider audience for your pharma business. However, if you want to get the most out of your Google Ads campaigns, you need to optimize them for SEO. Here are some tips on how to increase SEO on Google Ads for the pharma industry: Use relevant keywords: When you’re creating your Google Ads campaigns, make sure to use relevant keywords.
Fierce Pharma
JULY 25, 2023
Patients with the eyelid disease Demodex blepharitis can now see a cure in Tarsus Pharmaceuticals’ Xdemvy, the first FDA-approved treatment for an ailment that affects some 25 million Americans.
PharmExec
JULY 26, 2023
As we approach the one-year anniversary of the IRA being signed into law, questions remain about how the new law will reverberate changes across the biopharma industry.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
MedCity News
JULY 27, 2023
RapidAI recently closed a $75 million Series C funding round led by Vista Credit Partners. The company offers an AI platform that helps hospital care teams triage and treat stroke patients more quickly.
Pharma Marketing Network
JULY 25, 2023
Traditionally, pharmaceutical companies have relied on demographics to target their marketing efforts. This means that they have focused on reaching consumers based on factors such as age, gender, income, and location. While demographics can be a useful starting point, they are not always enough to create effective marketing campaigns. This is because consumers are not just defined by their demographics.
Fierce Pharma
JULY 26, 2023
With a European approval for chronic kidney disease nod in hand, Boeringer Ingelheim and Eli Lilly's Jardiance is looking to catch up to AstraZeneca's Farxiga in this use and continue growing its r | After recent label expansions in the U.S. and Europe paid off with a sizable sales increase for Jardiance, the drug has added a third use to its European label.
PharmExec
JULY 27, 2023
Frederique Welgryn, global vice president for women's health, Perrigo, shares insight into the approval of Opill (norgestrel), a progestin-only contraception, in this exclusive Q&A.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
MedCity News
JULY 27, 2023
Biohaven’s bid to bring to market the first drug for rare neuromuscular disorder spinocerebellar ataxia has hit a setback. The FDA is refusing to review the drug’s application, a decision that could indicate the agency wants another clinical trial.
PM360
JULY 26, 2023
An initial and discernible benefit to adopting decentralized clinical trial (DCT) models is alleviating patient burden by mitigating unnecessary travel through the utilization of eClinical platforms, mobile phlebotomy/nursing services, local clinics, and other technologies. For example, oncology patients with end-stage cancers participating in traditional clinical trials would be required to travel, often substantial distances several times a week, to a research/academic site for something as si
Fierce Pharma
JULY 25, 2023
Just as the calls for a business separation grow louder at Bayer, the company’s weedkiller performance is bolstering the argument with dramatically declining sales. | Just as the calls for a business separation grow louder at Bayer, the company’s weedkiller performance is bolstering the argument with dramatically declining sales.
Pharmaceutical Commerce
JULY 25, 2023
With FDA’s compliance deadline only three months away, the tech-supply chain partnership is expected to help manufacturers and wholesalers meet the Nov. 27 deadline.
Advertiser: ZoomInfo
In times of economic uncertainty, account-based strategies are essential. According to several business analysts and practitioners, ABM is a necessity for creating more predictable revenue. Research shows that nearly three-quarters of marketers (74%) already have the resources needed to build successful ABM programs.
Expert insights. Personalized for you.
52 
Let's personalize your content